6-methylthiopurine has been researched along with Colitis, Granulomatous in 16 studies
6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 9.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD)." | 7.71 | Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. ( Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001) |
| "A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration-adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2." | 5.12 | 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. ( Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007) |
| "Thiopurines (azathioprine, 6-mercaptopurine) are a mainstay of treatment in Crohn disease (CD)." | 3.80 | Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. ( Amre, D; Deslandres, C; Kopylov, U; Seidman, EG; Theoret, Y, 2014) |
| "6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven efficacy in the treatment of Crohn disease (CD)." | 3.71 | Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. ( Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001) |
| " For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported." | 2.44 | Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007) |
| "We assessed the incidence and predictive factors of thiopurine-induced adverse events (AE) resulting in therapy cessation in pediatric inflammatory bowel disease (IBD), related to thiopurine metabolites and biochemical abnormalities, and determined overall drug survival." | 1.72 | Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. ( Benninga, MA; Buiter, HJC; de Boer, NKH; de Meij, TGJ; Jagt, JZ; Pothof, CD; van Limbergen, JE; van Wijk, MP, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martín-Masot, R | 1 |
| Ortiz Pérez, MP | 1 |
| Ramos Rueda, N | 1 |
| Serrano Nieto, J | 1 |
| Blasco-Alonso, J | 1 |
| Navas-López, VM | 1 |
| Thomsen, SB | 1 |
| Allin, KH | 1 |
| Burisch, J | 1 |
| Jensen, CB | 1 |
| Hansen, S | 1 |
| Gluud, LL | 1 |
| Theede, K | 1 |
| Kiszka-Kanowitz, M | 1 |
| Nielsen, AM | 1 |
| Jess, T | 1 |
| Jagt, JZ | 1 |
| Pothof, CD | 1 |
| Buiter, HJC | 1 |
| van Limbergen, JE | 1 |
| van Wijk, MP | 1 |
| Benninga, MA | 1 |
| de Boer, NKH | 1 |
| de Meij, TGJ | 1 |
| Pospisilova, K | 1 |
| Siroka, J | 1 |
| Karaskova, E | 1 |
| Hradsky, O | 1 |
| Lerchova, T | 1 |
| Zarubova, K | 1 |
| Copova, I | 1 |
| Gonsorcikova, L | 1 |
| Velganova-Veghova, M | 1 |
| Francova, I | 1 |
| Urbanek, L | 1 |
| Geryk, M | 1 |
| Mihal, V | 1 |
| Bronsky, J | 1 |
| Kopylov, U | 2 |
| Amre, D | 1 |
| Theoret, Y | 1 |
| Deslandres, C | 1 |
| Seidman, EG | 2 |
| Battat, R | 1 |
| Benmassaoud, A | 1 |
| Paradis-Surprenant, L | 1 |
| Chua, EW | 1 |
| Cree, S | 1 |
| Barclay, ML | 1 |
| Doudney, K | 1 |
| Lehnert, K | 1 |
| Aitchison, A | 1 |
| Kennedy, MA | 1 |
| Rahhal, RM | 1 |
| Bishop, WP | 2 |
| Haines, ML | 1 |
| Ajlouni, Y | 1 |
| Irving, PM | 1 |
| Sparrow, MP | 1 |
| Rose, R | 1 |
| Gearry, RB | 1 |
| Gibson, PR | 1 |
| Wright, S | 1 |
| Sanders, DS | 1 |
| Lobo, AJ | 1 |
| Lennard, L | 1 |
| Goldenberg, BA | 1 |
| Rawsthorne, P | 1 |
| Bernstein, CN | 1 |
| Wusk, B | 1 |
| Kullak-Ublick, GA | 1 |
| Rammert, C | 1 |
| von Eckardstein, A | 1 |
| Fried, M | 1 |
| Rentsch, KM | 1 |
| Banerjee, S | 1 |
| Reinshagen, M | 1 |
| Schütz, E | 1 |
| Armstrong, VW | 1 |
| Behrens, C | 1 |
| von Tirpitz, C | 1 |
| Stallmach, A | 1 |
| Herfarth, H | 1 |
| Stein, J | 1 |
| Bias, P | 1 |
| Adler, G | 1 |
| Shipkova, M | 1 |
| Kruis, W | 1 |
| Oellerich, M | 1 |
| von Ahsen, N | 1 |
| Swaminath, A | 1 |
| Kornbluth, A | 1 |
| Belaiche, J | 1 |
| Desager, JP | 1 |
| Horsmans, Y | 1 |
| Louis, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL[NCT02046694] | Early Phase 1 | 34 participants (Actual) | Interventional | 2014-01-06 | Completed | ||
| Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649] | 388 participants (Actual) | Observational | 2002-03-01 | Completed | |||
| Chronotherapy in Inflammatory Bowel Disease[NCT04304950] | Phase 4 | 28 participants (Actual) | Interventional | 2016-04-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is to examine if the intervention results in a lower level of 6-Methylmercaptopurine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10 ^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 2395.27 |
| Morning Group Medication Administration | 825.15 |
Harvey Bradshaw Activity Index has 5 questions. The final score is totaled and will fall into the following categories, which are used to define the severity of the disease: >16 severe diseases, 8-16 moderate disease, 5-7 mild disease, <5 remission. Scores range from 0 ( lowest possible score) to 17. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 2.15 |
| Morning Group Medication Administration | 3.09 |
This questionnaire is used to collect primary sleep times, such as bed- and rise-times, including the time a person is fully awake, sleep latency and inertia, in addition to other time points. The MCTQ uses the midpoint of sleep between sleep onset and offset to assess chronotype. Chronotype is your body's natural time to be awake or asleep at certain times. Total scores can range from 16 to 86, with the lowest values representing extreme-late chronotype. For this study corrected midpoint of sleep (MSFc) was calculated. This information is combined to determine the mean time of day at which respondents were more likely to feel most alert. The numbers provided in the outcome measure data table represent time (hour and minute). The hour has been converted to military time and the minutes were converted to decimals. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | hours (Mean) |
|---|---|
| Evening Group Medication Administration | 3.70 |
| Morning Group Medication Administraion | 2.57 |
Quality of Life Measure Score:1-7 (The higher the number the greater the quality of life) (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 5.83 |
| Morning Group Medication Administration | 5.91 |
This is to examine if the intervention results in a greater level of thioguanine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 175.04 |
| Morning Group Medication Administration | 225.65 |
1 review available for 6-methylthiopurine and Colitis, Granulomatous
| Article | Year |
|---|---|
Optimizing drug therapy in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
1 trial available for 6-methylthiopurine and Colitis, Granulomatous
| Article | Year |
|---|---|
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Crohn Disease; Dose-Response Relati | 2007 |
14 other studies available for 6-methylthiopurine and Colitis, Granulomatous
| Article | Year |
|---|---|
[Laboratory determination of thiopurine levels in paediatric patients with inflammatory bowel disease].
Topics: Adolescent; Child; Child, Preschool; Chromatography, Liquid; Colitis, Ulcerative; Crohn Disease; Dos | 2020 |
Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Topics: Adult; Allopurinol; Azathioprine; Colitis, Ulcerative; Crohn Disease; Denmark; Drug Therapy, Combina | 2020 |
Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Topics: Adolescent; Antimetabolites; Azathioprine; Biomarkers, Pharmacological; Child; Cohort Studies; Colit | 2022 |
Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.
Topics: Adolescent; Azathioprine; Biomarkers; Child; Crohn Disease; Drug Therapy, Combination; Female; Human | 2021 |
Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease.
Topics: Adolescent; Azathioprine; Chemical and Drug Induced Liver Injury; Child; Crohn Disease; Female; Guan | 2014 |
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.
Topics: Anti-Inflammatory Agents; Azathioprine; Biomarkers; Colitis, Ulcerative; Crohn Disease; Cross-Sectio | 2015 |
Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Comparative Genomic Hybridization; Crohn Disease; DNA Copy | 2015 |
Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
Topics: Adolescent; Allopurinol; Antimetabolites; Child; Child, Preschool; Cohort Studies; Colitis, Ulcerati | 2008 |
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Cr | 2011 |
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Azathioprine; Child; | 2004 |
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Topics: Adult; Azathioprine; Biomarkers; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Dose-Response R | 2004 |
Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cohort Studi | 2004 |
Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Erythr | 2006 |
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Topics: Adult; Azathioprine; Case-Control Studies; Crohn Disease; Drug Monitoring; Drug Therapy, Combination | 2001 |